Molecular Templates, Inc. (NASDAQ:MTEM)
Industry: Healthcare

Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.

Current Quote*
Last: $5.080
Change: 0.030
Book: $1.935
Volume: 19,279

As Of: 08/16 13:12 ET
*Quotes delayed by 20min.

Graphs for MTEM

3 Month Graph

6 Month Graph

1 Year Graph